參考價	￥ 880

信號通路

MedChemExpress (M

CAS	629664-81-9	純度	99.76%
分子量	438.47	分子式	C??H??F?N?O?
供貨周期	現(xiàn)貨	規(guī)格	10 mM * 1 mL
貨號	HY-50911	應用領域	醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥

Turofexorate isopropyl (FXR-450) 是一種有效的，具有口服活性的，選擇性 FXR 激動劑，EC50 為 4 nM。

詳細介紹

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務。

Turofexorate isopropyl

CAS No. : 629664-81-9

MCE 國際站：Turofexorate isopropyl

產(chǎn)品活性：Turofexorate isopropyl (FXR-450) 是一種有效的，具有口服活性的，選擇性 FXR 激動劑，EC₅₀ 為 4 nM。

研究領域：Metabolic Enzyme/Protease | Autophagy

作用靶點：FXR | Autophagy

In Vitro: Turofexorate isopropyl (WAY-362450) is a potent, selective, and orally bioavailable FXR agonist (EC₅₀=4 nM). Turofexorate isopropyl (WAY-362450) is highly selective, as no significant cross-reactivity with these receptors (LXRα, LXRβ, PPARα, PPARγ, PPARδ, RXRα, RARγ, VDR, SXR, ERα, ERβ, GR, AR, MR, and PR) is observed at concentrations up to 10 μM. WAY-362450 displays potent agonist activity in the FXR reporter gene assays and on FXR target genes in cell-based assays. In promoter assays, utilizing reporter constructs under control of the human bile salt excretory pump (BSEP), human small heterodimer partner (SHP), and mouse intestinal bile acid binding protein (IBABP) genes are up-regulated by Turofexorate isopropyl (WAY-362450) with EC₅₀ of 17, 230, and 33 nM, respectively. In addition, WAY-362450 significantly induces mRNAs encoding for BSEP, SHP, and IBABP in human cell cultures at 1 μM (13-, 2-, and 20-fold, respectively). Turofexorate isopropyl (WAY-362450) potently induces luciferase reporter expression with an EC₅₀ of 16 nM. Turofexorate isopropyl (WAY-362450) is a potent stimulator of endogenous FXR gene activation in mouse AML12 cells and in primary human hepatocytes.

In Vivo: Turofexorate isopropyl (WAY-362450) also shows potent effects on cholesterol and triglyceride lowering in LDLR^-/- mice and antiatherogenic activity with respect to reduction of aortic arch lesions. Oral administration of Turofexorate isopropyl (WAY-362450) to LDLR^-/- mice results in lowering of cholesterol and triglycerides. Chronic administration in an atherosclerosis model results in significant reduction in aortic arch lesions. Turofexorate isopropyl (WAY-362450) is dosed in rat at 3 mg/kg (po and iv) and shows good oral bioavailability (38%). There is a protracted half-life of 25 h, modest volume of distribution, and low clearance (3.3 L/kg, ~10% of hepatic blood flow). Additional pharmacokinetic studies in mice and higher species have been completed, and the data will be reported elsewhere. In rats, Turofexorate isopropyl (WAY-362450) results in an elevation in HDLc levels, whereas in hamsters it causes a reduction similar to that observed in mice Treatment of wild-type mice with 30 mg/kg Turofexorate isopropyl (WAY-362450) results in induction of SHP expression in wild-type mice but not in FXR^-/- mice. Consistent with the known effects of SHP induction on bile acid synthetic gene expression, Turofexorate isopropyl (WAY-362450) strongly represses expression of the CYP8B1 bile acid synthetic gene in wild-type mice but had no effect on CYP8B1 gene expression in FXR^-/- mice.